Novo’s outgoing CEO prepares to hand off business as sales threats from Lilly, GLP-1 compounders persist

Novo Nordisk veteran Maziar Mike Doustdar—who is set to assume the role of CEO on Thursday—will have his work cut out turning things around at the Danish drugmaker, which is facing a commercial rec | Novo Nordisk veteran Maziar Mike Doustdar—who is set to assume the role of CEO on Thursday—will have his work cut out turning things around at the Danish drugmaker. On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders continue to chip away at sales of Novo’s branded GLP-1 medicines Ozempic and Wegovy.Read More